ReviewJournal of advanced research2021
Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection.
Review in Journal of advanced research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.Emerging microbes & infections · 2022Pooled it
- SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature.International journal of environmental research and public health · 2021Pooled it
- Transcriptomics-driven antiviral drug screening identifies ATF6 as a homeostatic regulator of ER stress and innate immunity.Journal of advanced research · 2026Article
- Explainable machine learning-based mortality risk stratification for older adults with COVID-19: pinpointing core immunological biomarkers and revealing dose-threshold effects.Frontiers in immunology · 2026Article
- The characteristics of gut microbiota composition in patients with depression and relationship with clinical symptoms.Frontiers in psychiatry · 2026Article
- Herd Immunity to SARS-CoV-2 Among the Armenian Population in the Second Half of 2022.Epidemiologia (Basel, Switzerland) · 2025Article
- Antibody-dependent enhancement of coronaviruses.International journal of biological sciences · 2025Review
- Enhanced immunity effect of Korean Red Ginseng capsule: A randomized, double-blind and placebo-controlled clinical trial.Journal of ginseng research · 2024Article
- CD66bJournal of extracellular vesicles · 2024Article
- The role of HMGB1 in COVID-19-induced cytokine storm and its potential therapeutic targets: A review.Immunology · 2023Review
- Multi-omics data reveals the important role of glycerophospholipid metabolism in the crosstalk between gut and brain in depression.Journal of translational medicine · 2023Article
- Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant.Vaccines · 2022Article
- SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19.International journal of molecular sciences · 2022Review
- Article
- Differential Gut Microbiota Compositions Related With the Severity of Major Depressive Disorder.Frontiers in cellular and infection microbiology · 2022Article
- Gut Microbiota-Related Inflammation Factors as a Potential Biomarker for Diagnosing Major Depressive Disorder.Frontiers in cellular and infection microbiology · 2022Article
- Associations Between Disordered Microbial Metabolites and Changes of Neurotransmitters in Depressed Mice.Frontiers in cellular and infection microbiology · 2022Article
- An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19.Frontiers in immunology · 2022Review
- SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway.PloS one · 2022Article
- Effects of vaccination, new SARS-CoV-2 variants and reinfections on post-COVID-19 complications.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 5 countries.
Funding
Abstract
Background: The recent ongoing outbreak of coronavirus disease 2019 (COVID-19), still is an unsolved problem with a growing rate of infected cases and mortality worldwide. The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is targeting the angiotensin-converting enzyme 2 (ACE2) receptor and mostly causes a respiratory illness. Although acquired and resistance immunity is one of the most important aspects of alleviating the trend of the current pandemic; however, there is still a big gap of knowledge regarding the infection process, immunopathogenesis, recovery, and reinfection. Aim of Review: To answer the questions regarding "the potential and probability of reinfection in COVID-19 infected cases" or "the efficiency and duration of SARS-CoV-2 infection-induced immunity against reinfection" we critically evaluated the current reports on SARS-CoV-2 immunity and reinfection with special emphasis on comparative studies using animal models that generalize their finding about protection and reinfection. Also, the contribution of humoral immunity in the process of COVID-19 recovery and the role of ACE2 in virus infectivity and pathogenesis has been discussed. Furthermore, innate and cellular immunity and inflammatory responses in the disease and recovery conditions are reviewed and an overall outline of immunologic aspects of COVID-19 progression and recovery in three different stages are presented. Finally, we categorized the infected cases into four different groups based on the acquired immunity and the potential for reinfection. Key Scientific Concepts of Review: In this review paper, we proposed a new strategy to predict the potential of reinfection in each identified category. This classification may help to distribute resources more meticulously to determine: who needs to be serologically tested for SARS-CoV-2 neutralizing antibodies, what percentage of the population is immune to the virus, and who needs to be vaccinated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.